TRANSGENE news, videos and press releases - Page 2
For more news please use our advanced search feature.
TRANSGENE - More news...
TRANSGENE - More news...
- Transgene’s Combined General Meeting of May 5, 2023
- Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
- Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
- Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
- Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
- Availability of Transgene’s 2022 Universal Registration Document
- Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
- Transgene Announces Upcoming Investor Meetings
- Transgene: 2022 Full-year Results and Business Update
- Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
- Transgene: Balance Sheet of the Liquidity Contract With Natixis Oddo BHF SCA as of December 31, 2022
- Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
- Transgene Announces Financial Calendar for 2023
- Transgene Announces Upcoming Investor Meetings
- Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
- Transgene Reports Business Update And Q3 2022 Financial Position
- Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
- R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
- Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
- Availability of Transgene’s Half-Year Financial Report as of June 30, 2022
- Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
- Transgene Announces Upcoming Investor Meetings
- Transgene: Balance Sheet of the Liquidity Contract With Natixis Oddo BHF SCA as of June 30, 2022
- Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®
- Transgene and BioInvent Announce Positive Progress for BT-001
- Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
- Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
- Transgene’s Combined General Meeting of May 25, 2022
